Sherrington Robin, EVP, Strategy & Innovation at Xenon Pharmaceuticals Inc. (XENE), sold 138,155 shares at $38.80 ($5.3M) on 2022-09-01, disclosed to the SEC on 2022-09-02.
Open-market sale of $5.3M XENE by EVP, Strategy & Innovation. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $37.86 | 1,572 | $60K | 1.1% |
| 2 | $38.57 | 21,352 | $824K | 15.6% |
| 3 | $38.57 | 21,352 | $824K | 15.6% |
| 4 | $38.03 | 35,103 | $1.3M | 25.2% |
| 5 | $38.03 | 35,103 | $1.3M | 25.2% |
| 6 | $38.80 | 8,776 |
| $341K |
| 6.4% |
| 7 | $38.80 | 8,776 | $341K | 6.4% |
| 8 | $38.81 | 6,121 | $238K | 4.5% |
| Total | $38.33 avg | 138,155 | $5.3M | 100% |
| Filing → |
| XENE | SELL | 2021-06-01 | $228K | — | Filing → |